UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5
UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.
Read original at benzingaStocks · News reference
8-K filing — CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
Filed: 2026-08-20 AccNo: 0001801170-26-000214 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 20, 2026, 8:06 PM
- Checked
- Aug 20, 2026, 8:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.
Read original at benzingaClover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Read original at benzinga